Montelukast Sun Pharma Italia Srl

Montelukast, the active ingredient in Montelukast Sun Pharma Italia Srl, is a leukotriene receptor antagonist presented as an oral dosage form for oral use. It is indicated for the management of asthma, exercise‑induced bronchoconstriction and allergic rhinitis in adults and children.

GNH USA supplies Montelukast Sun Pharma Italia Srl as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control airway inflammation and bronchoconstriction. - Asthma: improves control of persistent asthma and reduces exacerbations. - Exercise‑induced bronchoconstriction: prevents narrowing of airways during physical activity. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching caused by seasonal or perennial allergens.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: occasional discomfort. - Cough: transient irritation. - Nausea: occasional upset stomach. - Diarrhoea: loose stools. - Fatigue: feeling of tiredness.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips or tongue. - Stevens‑Johnson syndrome: severe skin reaction. - Eosinophilic granulomatosis with polyangiitis: rare vasculitis. - Hepatic injury: abnormal liver enzymes. - Anaphylaxis: life‑threatening allergic response. - Neuropsychiatric events: mood changes, including suicidal thoughts.

Before prescribing Montelukast, clinicians should consider several safety aspects. - Liver function monitoring: assess hepatic status in patients with existing liver disease. - Neuropsychiatric vigilance: watch for mood alterations, depression or suicidal ideation. - Caution in severe hepatic impairment: dose adjustment may be required. - Hypersensitivity avoidance: discontinue if signs of allergic reaction appear. - Pregnancy risk assessment: category B, discuss benefits versus potential risks. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Montelukast may interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase montelukast plasma levels. - Phenobarbital or rifampicin: may reduce therapeutic effect by inducing metabolism. - Ritonavir (HIV protease inhibitor): can raise exposure and risk of adverse events.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors: may heighten neuropsychiatric risk. - β2‑agonists: additive bronchodilator effect may require dose adjustment. - Non‑steroidal anti‑inflammatory drugs: possible increase in rash or hypersensitivity reactions.